IXICO plc Grant of Share Options (3797W)
February 09 2017 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 3797W
IXICO plc
09 February 2017
9 February 2017
IXICO plc
("IXICO" or the "Company")
Share option grant to Directors
IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the brain
health company, today announces that on 7 February 2017 the
Remuneration Committee agreed to grant options to the Company's
Executive Directors and employees in accordance with the rules of
the Company's EMI Share Option Plan 2014(the 'Plan') exercisable at
a price of 36.5p.
The award of options under the Plan are over the ordinary shares
in the Company and are subject to performance conditions. The
options will vest upon the achievement of strategic corporate goals
in respect of commercialisation of the Company's products and/or
services or a significant corporate development transaction within
three years of the date of grant.
The total number of options being issued at this time is
1,044,698. The following table sets out the details of the options
that have been granted to the Executive Directors:
Name of Director Number of Total number Percentage of
options of options held issued share
granted capital under
option
------------------ ---------- ----------------- ---------------
Giulio Cerroni 676,582 676,582 2.5%
------------------ ---------- ----------------- ---------------
Derek Hill 80,000 540,236 2.0%
------------------ ---------- ----------------- ---------------
Susan Lowther 80,000 490,196 1.8%
------------------ ---------- ----------------- ---------------
For further information please contact:
IXICO plc
Charles Spicer, Non-Executive Chairman Tel: +44 20 3763
Susan Lowther, Chief Financial Officer 7499
and Company Secretary
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, Parkinson's disease,
behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUWANRBVAURAR
(END) Dow Jones Newswires
February 09, 2017 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2023 to Apr 2024